Tonix Pharmaceuticals (US:TNXP) Globenewswire·2025-10-09 11:00Core Viewpoint - Tonix Pharmaceuticals Holding Corp. is actively participating in the World Vaccine Congress–Europe 2025, showcasing its advancements in vaccine development, particularly the TNX-801 Mpox vaccine, which is aimed at enhancing vaccine effectiveness against infectious diseases [1][3]. Company Overview - Tonix Pharmaceuticals is a fully-integrated biotechnology company with marketed products and a diverse pipeline of development candidates, focusing on central nervous system disorders, immunology, rare diseases, and infectious diseases [4]. - The company has received FDA approval for Tonmya, a first-in-class non-opioid analgesic for fibromyalgia, marking the first new prescription medicine approval for this condition in over 15 years [4]. - Tonix's development portfolio includes treatments for acute migraine, acute stress reaction, major depressive disorder, organ transplant rejection, autoimmune diseases, and infectious diseases [4]. Upcoming Conference Details - Dr. Sina Bavari will present on the safety, durability, and protection of the single-dose TNX-801 Mpox vaccine on October 15, 2025 [3]. - A panel discussion moderated by Dr. Zeil Rosenberg will focus on enhancing vaccine effectiveness, using Mpox as a model, featuring experts from Tonix and other institutions [3].